{"id":698,"date":"1998-04-01T12:01:00","date_gmt":"1998-04-01T10:01:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/1998\/hirudine"},"modified":"1998-04-01T12:01:00","modified_gmt":"1998-04-01T10:01:00","slug":"hirudine","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/1998\/hirudine","title":{"rendered":"Hirudine"},"content":{"rendered":"<p>Zusammenfassung: Hirudin und seine Strukturverwandten sind effektive, aber auch teure Alternativen zum Heparin. Sie bieten einige Vorteile wie konstantere Wirkspiegel im Blut und leichtere Steuerbarkeit. Die Antikoagulation ist, besonders in h\u00f6heren Dosen, st\u00e4rker als bei den Heparinen, allerdings zum Preis h\u00e4ufigerer Blutungskomplikationen. Daher sind die meisten gro\u00dfen Studien zu instabiler Angina pectoris, Myokardinfarkt und Ballondilatation [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Zusammenfassung: Hirudin und seine Strukturverwandten sind effektive, aber auch teure Alternativen zum Heparin. Sie bieten einige Vorteile wie konstantere Wirkspiegel im Blut und leichtere Steuerbarkeit. Die Antikoagulation ist, besonders in h\u00f6heren Dosen, st\u00e4rker als bei den Heparinen, allerdings zum Preis h\u00e4ufigerer Blutungskomplikationen. Daher sind die meisten gro\u00dfen Studien zu instabiler Angina pectoris, Myokardinfarkt und Ballondilatation [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[495,61,1784,1749,544,1786,1785,1792,98,99,1790,71,687,1791,100,1789,1793,1788,85,86,498,1771,69,65,1787,83,84,87,79,54,51,1783,1781,1782,55],"class_list":["post-698","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-angina-pectoris","tag-beinvenenthrombose","tag-danaparoid-natrium","tag-desirudin","tag-enoxaparin","tag-gusto-iia-studie","tag-gusto-iib-studie","tag-helvetica-studie","tag-heparin","tag-heparininduzierte-thrombozytopenie","tag-hero-studie","tag-herzinfarkt","tag-hirudin","tag-hirulog","tag-hit","tag-hit-ii-studie","tag-hit-iii-studie","tag-hit-iv-studie","tag-koronarangiografie","tag-koronarangiographie","tag-koronare-herzkrankheit","tag-lepirudin","tag-lungenembolie","tag-myokardinfarkt","tag-oasis-studie","tag-pci","tag-perkutane-koronarintervention","tag-perkutane-transluminale-koronare-angioplastie","tag-ptca","tag-thromboembolie","tag-thrombose","tag-timi-5-studie","tag-timi-9a-studie","tag-timi-9b-studie","tag-venenthrombose"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/698","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=698"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/698\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=698"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=698"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=698"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}